David S. Grayzel - Insider Trading & Ownership

Location
C/O Surface Oncology, 50 Hampshire St., 8 Th Floor, Cambridge, MA
Summary
The estimated net worth of David S. Grayzel is at least $50.9M dollars as of October 27, 2025. David S. Grayzel is the Director of Aerovate Therapeutics, Inc. and owns shares of Jade Biosciences, Inc. (JBIO) stock worth about $50.9M. David S. Grayzel is the Director of Q32 Bio Inc. and owns shares of Q32 Bio Inc. (QTTB) stock worth about $34.5K.
Signature
/s/ Eric Bell, Attorney-in-Fact
All Insider Reports
All Insider Reports

Ownership of David S. Grayzel

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
JBIO Jade Biosciences, Inc. Director $50.9M Jun 5, 2024
QTTB Q32 Bio Inc. Director $34.5K Oct 23, 2025
SURF Surface Oncology, Inc. Director Sep 8, 2023

Insider Transactions Reported by David S. Grayzel:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.